<DOC>
	<DOCNO>NCT00669877</DOCNO>
	<brief_summary>The goal clinical research study learn intensive chemotherapy give 6 month help control cure Burkitt 's leukemia , Burkitt 's lymphoma , small non-cleaved cell B-cell leukemia lymphoma . Another goal see well treatment work give Rituximab . The safety combine treatment also study .</brief_summary>
	<brief_title>Rituximab Hyper-CVAD ( Cyclophosphamide , Vincristine , Adriamycin , Dexamethasone ) Burkitt 's Burkitt 's -Like Leukemia/Lymphoma</brief_title>
	<detailed_description>The hyper-CVAD regimen combination chemotherapy drug include cyclophosphamide , vincristine , Adriamycin , dexamethasone give together one `` course '' treatment . This alternate course combination chemotherapy drug methotrexate cytarabine . Rituximab protein ( monoclonal antibody ) attach surface leukemia lymphoma cell marker call cluster differentiation antigen 20 ( CD20 ) . During treatment , participant physical exam give blood sample ( 1 tablespoon ) least twice week . After two course chemotherapy , test do treatment repeat check response . In patient leukemia , bone marrow sample repeat 2 3 week begin treatment check response . All participant study receive 2 kind chemotherapy course total 8 course . Chemotherapy course give large vein central venous catheter ( plastic tube usually place collarbone ) . In Course 1 ( odd course ) , participant receive rituximab vein 6 hour Days 1 11 . Participants receive drug acetaminophen ( Tylenol ) diphenhydramine hydrochloride ( Benadryl ) 30-60 minute dose rituximab . This do lessen risk fever , chill , allergic reaction . Usually , first dose rituximab require 6 hour complete . Participants receive cyclophosphamide vein 2-3 hour every 12 hour total 6 dos , give 3 day ( Days 1 , 2 , 3 ) . Adriamycin give vein 24 hour Day 4 . Vincristine give vein 15 30 minute Days 4 11 along dexamethasone mouth vein Days 1-4 11-14 . Participants also receive pegfilgrastim G-CSF ( growth stimulate colony factor ) help rapid recovery normal bone marrow start course chemotherapy finish . Pegfilgrastim inject skin within 72 hour completion cycle chemotherapy . G-CSF give injection vein skin blood count recover . Treatment brain give inside spinal fluid cytarabine methotrexate Days 2 7 course help prevent leukemia develop . For patient 60 year old , first course give protective isolation room decrease risk infection ( ) . In Course 2 ( even course ) , participant receive rituximab infusion 4 hour Days 1 8 . They receive methotrexate infusion 24 hour first day , cytarabine high dose 2 hour every 12 hour 4 dos ( Days 2 3 ) . Citrovorum factor ( leucovorin ) give vein mouth 2-3 day ( Day 2 ) decrease risk side effect methotrexate . G-CSF give Course 1 ( chemotherapy finish ) . The treatment brain inside spinal fluid give course 1 day 2 7 . After two course therapy , response treatment check . If leukemia lymphoma responding , therapy continue total 8 course 6 month . Therapy stop leukemia lymphoma start get bad . An Ommaya reservoir may also place surgically route treat leukemia brain decrease risk leukemia patient difficulty spinal treatment . An Ommaya reservoir tube insert skin scalp enters spinal fluid cavity brain . This investigational study . All drug study commercially available . Their use together study investigational . About 70 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Burkitt 's Burkittlike leukemia and/or lymphoma , either previously untreated , previously treat ( may CR active disease 12 course chemotherapy ) , HIVrelated . 2 . All age eligible . 3 . Zubrod performance status &lt; 3 ( ECOG Scale , Appendix A ) . 4 . Adequate liver function ( bilirubin &lt; 3.0 mg/dL , unless consider due tumor ) , renal function ( creatinine &lt; 3.0 mg/dL , unless consider due tumor ) . 5 . Signed informed consent . 1 ) N/A</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Burkitt 's Lymphoma</keyword>
	<keyword>Burkitt 's Like Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Hyper-CVAD</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Cytarabine</keyword>
</DOC>